Protagonist Therapeutics Inc
PTGXHealthcare|Biotechnology|USA
$131.42
-6.22 (-4.52%)
DCF (FCF)
$3.72
Tangible Book
$10.21
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2026
P3
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
NCT06033586